June 24, 2017

Welcome Address D. Robert Siemens VIEW
Canadian Urologic Oncology Group Lecture - Telling tales of precision oncology in CRPC Martin E. Gleave VIEW
State-of-the-Art Lecture 1 - Optimizing active surveillance for prostate cancer Stacy Loeb VIEW
Educational Forum 1    
Enhancing prostate cancer screening and care in 2017 using radiological and molecular advances made in the last decade    
Session introduction by David Penson followed by
Nutrition, Exercise and weight loss in Prostate Carcinoma by J. Brantley Thrasher
David Penson / 
J. Brantley Thrasher
Prostate Cancer Screening: "Official" Canadian Perspective Neil E. Fleshner VIEW
The Utility of Serum and Urine Markers to Select Patients for Initial and Repeat Biopsy Stacy Loeb VIEW
The Role of mpMRI in Active Surveillance Franck Bladou VIEW
The Role of Multiparametric MRI in Prostate Cancer Screening Franck Bladou VIEW
The Future of PSA Screening Laurence H. Klotz VIEW

June 25, 2017

State-of-the-Art Lecture 2 - Immunotherapy for urologic cancers Kim Chi VIEW
Educational Forum 2    
Optimizing quality of care in bladder cancer Peter Chung VIEW
Girish S. Kulkarni VIEW
Bobby Shayegan VIEW
Adrian Fairey VIEW
State-of-the-Art Lecture 3 - What's important in infertility 2017 Peter Schlegel VIEW
Podium Session 1: Early Prostate Cancer    
Magnetic resonance imaging-targeted vs. systematic biopsies in men on active surveillance: Results of a prospective, randomized Canadian Urology Research Consortium trial Laurence H. Klotz VIEW
Germline mutations in the kallikrein 6 region and predisposition for aggressive prostate cancer Alexandre Zlotta VIEW
Association between germline genetic variation and progression in men with low-risk prostate cancer on active surveillance Viranda Jayalath VIEW
Defining a cohort of men who may not require repeat prostate biopsy based on the negative predictive value of PCA3 and magnetic resonance imaging combined: The double-negative effect Nathan Perlis VIEW
Prostate-specific antigen levels in men aged 60?70 and development of lethal prostate cancer over 30 years: Implications for risk-stratified screening Mark A. Preston VIEW
Outcomes of an aggressive biopsy strategy in young men with prostate-specific antigen between 0.5 and 2.5 Hanan Goldberg VIEW
CUA Historian Jerzy B. Gajewski VIEW
CUA Scholarship Foundation Lecture - The essential role of urology in transplantation: For service for innovation Patrick P. Luke VIEW
Allied Urological Association Address    
Allied Urological Association Address Brant Thrasher VIEW
Christopher Chapple VIEW
Mark Speakman VIEW
Educational Forum 3    
First do no harm: Avoiding urological overtreatment Luc Valiquette VIEW
Trustin S. Domes VIEW
Timothy Averch VIEW
Patrick Richard VIEW
State-of-the-Art Lecture 4 - Twins separated at birth: Vesicoureteral reflux and prostate cancer Barry Kogan VIEW
Educational Forum 4    
Building the bridge of transition Melise Keays VIEW
Barry Kogan VIEW
Blayne K. Welk VIEW

June 26, 2017

State-of-the-Art Lecture 5 - The contemporary use of mesh in prolapse and incontinence surgery J. Christian Winters VIEW
Educational Forum 5- Still leaking, now what? Refractory OAB, recurrent SUI and mesh concerns J. Christian Winters VIEW
Podium Session 2: General Urology    
Incidence, treatment and risk of adverse birth outcomes for kidney stones in pregnancy: A population-based study Michael Ordon VIEW
Evaluating the efficacy and safety of intravesical onabotulinumtoxinA in older patients with idiopathic overactive bladder Adiel E. Mamut VIEW
Low risk of clean intermittent catheterization and improved treatment response in a post-hoc analysis of a diverse age group of onabotulinumtoxinA-treated patients with overactive bladder Sidney B. Radomski VIEW
Randomized, controlled trial comparing narrow vs. wide focal zones for shock wave lithotripsy of renal calculi Monica A. Farcas VIEW
Understanding simple cystectomy for benign disease: A unique patient cohort with significant risks Henry Tran VIEW
Educational Forum 6    
BPH emerging technologies / techniques: Way of the future or passing trend?

Mark Speakman VIEW
Christopher Chapple VIEW
Sidney B. Radomski VIEW
Naeem Bhojani VIEW
State-of-the-Art Lecture 7 - CAUS Lecture - Chasing zero: The safety imperative for Canadian health care Peter Pisters VIEW

June 27, 2017

State-of-the-Art Lecture 8 - Improving the quality of medical management of stone disease Timothy Averch VIEW
Educational Forum 7 - Optimizing stone surgery outcomes Timothy Averch VIEW
State-of-the-Art Lecture 9 - What’s new in patient-reported outcomes following treatment for localized prostate cancer? David Penson VIEW
Educational Forum 8    
Challenging issues in post-prostate cancer care Sender Herschorn VIEW
  Gregory Bailly VIEW
Challenging issues in post-prostate cancer care Brant Thrasher VIEW
Podium Session 4: Other Oncology    
Four vs. 10 months of induction androgen-deprivation therapy for intermittent therapy (the FIT trial): A prospective Canadian Urology Research Consortium randomized trial Laurence H. Klotz VIEW
Safety of minimizing intensity of followup on active surveillance for clinical stage I testicular germ cell tumours Matthew Da Silva VIEW
Long-term followup of small renal masses: A prospective cohort study Emily Whelan VIEW
Dense dose combination of methotrexate/vinblastine/doxorubicin/cisplatin vs. gemcitabine/cisplatin in patients with cT3-4a bladder cancer treated with radical cystectomy: A real-world experience Wassim (Wes) Kassouf VIEW
A propensity score analysis of radical cystectomy vs. bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic Girish S. Kulkarni VIEW
Phase 2 randomized trial of rectus sheath vs. epidural blockade for postoperative analgesia in bladder cancer patients undergoing open radical cystectomy: Results of a data monitoring committee-mandated interim analysis Alexandra Bascom VIEW
CUA Guidelines    
Adult Overactive Active Bladder (OAB) Guideline Lysanne Campeau VIEW
Management of Muscle Invasive Bladder Cancer (MIBC) Guideline Girish S. Kulkarni VIEW
Canadian Urological Association recommendations on prostate cancer screening and early diagnosis Ross Mason VIEW